1. Home
  2. BGB vs YDES Comparison

BGB vs YDES Comparison

Compare BGB & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

BGB

Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

HOLD

Current Price

$11.42

Market Cap

512.5M

Sector

Finance

ML Signal

HOLD

YDES

YD Bio Limited Ordinary Shares

N/A

Current Price

$5.20

Market Cap

543.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BGB
YDES
Founded
2012
2013
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
512.5M
543.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BGB
YDES
Price
$11.42
$5.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
123.3K
14.5K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
9.75%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.85
$4.73
52 Week High
$12.65
$25.00

Technical Indicators

Market Signals
Indicator
BGB
YDES
Relative Strength Index (RSI) 54.96 40.74
Support Level $11.16 $4.73
Resistance Level $11.48 $5.37
Average True Range (ATR) 0.09 0.21
MACD 0.01 0.09
Stochastic Oscillator 63.16 62.59

Price Performance

Historical Comparison
BGB
YDES

About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Share on Social Networks: